Samsung Biologics target to develop broad Gap in CDMO sector

Reportedly Samsung Biologics plans to develop a fifth plant in Songdo, Incheon, Korea by investing more than 1 trillion won. Earlier this year, the company carried out a plan to build a second campus in October. And subsequently, invest 7.5 trillion won in the making of its fifth and sixth factories. Notably, it is one of the biggest contract development and manufacturing organization (CDMO) in the world. Also, Lonza, which is a traditional CDMO powerhouse has a yearly production capacity of 330,000 liters.

As per industry insider afresh, Plant 5 will be going to build with an annual capacity of 180,000 liters. Whereas, Plant 1 on Campus 1 has a capacity of 30,000 liters, Plant 2 154,000 liters, Plant 3 180,000 liters, and Plant 4 240,000 liters respectively.

While believing industry insiders, Samsung Biologics facility enlargement reflects the company will consistently win orders from global pharmaceutical companies. This is achieved by securing CDMO plants at a level that has a broad gap with its competitors. Recently, on March 2, Samsung Biologics come upon a drug CDMO deal that cost approx 241 billion won with Pfizer. And with the collaboration with Pfizer, Samsung Biologics has business relationships with seven of the top 10 worldwide pharmaceutical companies. As of now, Samsung Biologics is amiable in business with big companies such as Novartis, Roche, US Merck (MSD), Johnson & Johnson, BMS, and GSK.

“Plant 5’s capacity of 180,000 liters is based on antibody drugs,” an industry official said. “There is a possibility that production of next-generation drugs such as mRNA and antibody-drug conjugates (ADCs) will be added to the capacity in the future.”

FOLLOW US ON SOCIAL MEDIA – TelegramTwitterFacebook, & Google News.

Related Posts

Leave a Comment